KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $495.5 million.

  • Biogen's Cost of Revenue fell 1508.14% to $495.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.4 billion, marking a year-over-year increase of 405.99%. This contributed to the annual value of $2.4 billion for FY2025, which is 405.99% up from last year.
  • According to the latest figures from Q4 2025, Biogen's Cost of Revenue is $495.5 million, which was down 1508.14% from $674.4 million recorded in Q3 2025.
  • In the past 5 years, Biogen's Cost of Revenue ranged from a high of $674.4 million in Q3 2025 and a low of $275.0 million during Q1 2022
  • Moreover, its 5-year median value for Cost of Revenue was $577.2 million (2022), whereas its average is $557.9 million.
  • In the last 5 years, Biogen's Cost of Revenue crashed by 4248.07% in 2022 and then surged by 14101.82% in 2023.
  • Over the past 5 years, Biogen's Cost of Revenue (Quarter) stood at $660.1 million in 2021, then dropped by 13.51% to $570.9 million in 2022, then increased by 8.3% to $618.3 million in 2023, then fell by 5.63% to $583.5 million in 2024, then decreased by 15.08% to $495.5 million in 2025.
  • Its Cost of Revenue stands at $495.5 million for Q4 2025, versus $674.4 million for Q3 2025 and $605.0 million for Q2 2025.